https://www.pharmanow.live/latest-news/revuforj-approval-kmt2a-leukemia-oral-solid-dose-manufacturing
REVUFORJ Approval: GMP Implications for KMT2A Leukemia | Pharma Now
Syndax's REVUFORJ FDA approval for KMT2A leukemia in patients aged 1+ raises process validation and GMP demands for oral solid dose oncology manufacturers.
approvalgmpimplicationsleukemiapharma